How to prescribe Betmiga® (mirabegron) on overactive bladder?

被引：0
作者：
Rebibo, J. D. [1 ]
机构：
[1] CHU Rouen, Serv Neurol, 1 Rue Germont, F-76081 Rouen, France
来源：
PROGRES EN UROLOGIE | 2016年 / 26卷 / 03期
关键词：
Mirabegron; Overactive bladder; Anticholinergic; BETA(3)-ADRENOCEPTOR AGONIST; EFFICACY; PHASE-3; SAFETY;
D O I：
10.1016/j.fpurol.2016.08.001
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Overactive bladder (OAB) is defined by ICS (International Continence Society) as urgency, with or without urge incontinence, usually with frequency and nocturia. The pharmacological treatment was reduced to antimuscarinic. Recently, a new therapeutic class: beta 3-adrenoreceptor agonist is available in France, with encouraging results regarding its tolerance, main obstacle to good compliance regarding antimuscarinic treatment. However, further research is still needed to explore each subgroup as patient with lower urinary tract obstruction and neurological population. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：F61 / F62
页数：2
相关论文
共 8 条
  • [1] Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
  • [2] Aizawa N, 2012, NEUROUROL URODYNAM, V31, P895
  • [3] Mirabegron in Overactive Bladder: A Review of Efficacy, Safety, and Tolerability
    Chapple, Christopher R.
    Cardozo, Linda
    Nitti, Victor W.
    Siddiqui, Emad
    Michel, Martin C.
    [J]. NEUROUROLOGY AND URODYNAMICS, 2014, 33 (01) : 17 - 30
  • [4] Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder
    Chapple, Christopher R.
    Kaplan, Steven A.
    Mitcheson, David
    Klecka, Jiri
    Cummings, Jana
    Drogendijk, Ted
    Dorrepaal, Caroline
    Martin, Nancy
    [J]. EUROPEAN UROLOGY, 2013, 63 (02) : 296 - 305
  • [5] β3-Agonist Therapy: A New Advance in the Management of Overactive Bladder?
    Chapple, Christopher R.
    [J]. EUROPEAN UROLOGY, 2012, 62 (05) : 841 - 842
  • [6] Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial
    Khullar, Vik
    Amarenco, Gerard
    Angulo, Javier C.
    Cambronero, Javier
    Hoye, Kjetil
    Milsom, Ian
    Radziszewski, Piotr
    Rechberger, Tomasz
    Boerrigter, Peter
    Drogendijk, Ted
    Wooning, Marianne
    Chapple, Christopher
    [J]. EUROPEAN UROLOGY, 2013, 63 (02) : 283 - 295
  • [7] Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder
    Nitti, Victor W.
    Auerbach, Stephen
    Martin, Nancy
    Calhoun, Alaina
    Lee, Misun
    Herschorn, Sender
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04) : 1388 - 1395
  • [8] Mirabegron as a New Class of Oral Drug for Overactive Bladder Syndrome: Many Positive Perspectives, Some Concerns
    Novara, Giacomo
    Cornu, Jean-Nicolas
    [J]. EUROPEAN UROLOGY, 2013, 63 (02) : 306 - 308
1